| Sionna Therapeutics, Inc. |
Director |
Common Stock |
2.31M |
$84.1M |
$36.42 |
Oct 21, 2025 |
By Atlas Venture Fund XI, L.P. |
| Kymera Therapeutics, Inc. |
Director |
Common Stock |
723K |
$28.4M |
$39.26 |
Jul 9, 2024 |
Indirect |
| Sionna Therapeutics, Inc. |
Director |
Common Stock |
687K |
$25M |
$36.42 |
Oct 21, 2025 |
By Atlas Venture Opportunity Fund II, L.P. |
| Vigil Neuroscience, Inc. |
Director |
Stock Option Award (Right to Buy) |
0 |
$138K |
$7.62 |
Aug 5, 2025 |
Direct |
| Vigil Neuroscience, Inc. |
Director |
Common Stock |
0 |
$0 |
$2.41 |
Aug 5, 2025 |
By Atlas Venture Fund XII, L.P. |
| Vigil Neuroscience, Inc. |
Director |
Common Stock |
0 |
$0 |
$2.41 |
Aug 5, 2025 |
By Atlas Venture Opportunity Fund I, L.P. |
| Vigil Neuroscience, Inc. |
Director |
Common Stock |
0 |
$0 |
$2.41 |
Aug 5, 2025 |
Direct |
| Magenta Therapeutics, Inc. |
Director |
Stock Option (Right to Buy) |
20K |
|
|
Jun 28, 2022 |
Direct |
| Sionna Therapeutics, Inc. |
Director |
Non-Qualified Stock Option (right to buy) |
20K |
|
|
Jun 12, 2025 |
Direct |
| AVROBIO, Inc. |
Director |
Stock Option (Right to Buy) |
17.6K |
|
|
Jun 6, 2023 |
Direct |
| Kymera Therapeutics, Inc. |
Director |
Stock Option (Right to Buy) |
16K |
|
|
Jun 25, 2025 |
Direct |
| Sionna Therapeutics, Inc. |
Director |
Series A convertible preferred stock |
0 |
|
|
Feb 10, 2025 |
By Atlas Venture Fund XI, L.P. |
| Sionna Therapeutics, Inc. |
Director |
Series B convertible preferred stock |
0 |
|
|
Feb 10, 2025 |
By Atlas Venture Fund XI, L.P. |
| Sionna Therapeutics, Inc. |
Director |
Series C convertible preferred stock |
0 |
|
|
Feb 10, 2025 |
By Atlas Venture Fund XI, L.P. |
| Sionna Therapeutics, Inc. |
Director |
Series C convertible preferred stock |
0 |
|
|
Feb 10, 2025 |
By Atlas Venture Opportunity Fund II, L.P. |
| Sionna Therapeutics, Inc. |
Director |
Series Seed convertible preferred stock |
0 |
|
|
Feb 10, 2025 |
By Atlas Venture Fund XI, L.P. |